Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib (AZD4205) in relapsed or refractory PTCL
NCT04105010Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Sep 2019; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04105010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105010.